Vivus
FDA panel backs liraglutide for obesity
September 12, 2014Manufacturing and Production, Sales and Marketing Arena Pharmaceuticals, Belviq, Novo Nordisk, Qsymia, Victoza, Vivus, diabetes, obesity
An FDA panel has voted 14-1 to allow a form of Novo Nordisk’s type 2 diabetes treatment Victoza to help …
Doctor questions FDA’s diet drug approvals
August 23, 2013Research and Development, Sales and Marketing BMJ, Belviq, EMA, FDA, Vivus, diet pills, obesity
FDA approves new erectile dysfunction drug
April 30, 2012Sales and Marketing ED, FDA, Stendra. Pfizer, Vivus, viagra
The FDA has approved Vivus’ erectile dysfunction drug Stendra, and the firm hopes its rapid mode of action will help …
Obesity drug supported by FDA panel
February 23, 2012Sales and Marketing FDA, Qnexa, Vivus, Xenical, obesity
Vivus’ obesity drug Qnexa has been supported by an FDA panel, two years after it was knocked back by the …
Latest content
Major funding opportunity opens for early cancer diagnostics
September 4, 2026
Androlabs receives UK authorisation for new Testavan presentation
September 4, 2026
CEPI backs African-led Bundibugyo Ebola vaccine development
September 3, 2026
Cytomos appoints life sciences executive to board
September 2, 2026
